metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
metastatic/advanced - colorectal cancer (mCRC) metastatic/advanced - colorectal cancer (mCRC)
versus Standard of Care (SoC)
	atezolizumab plus cometinib
	Modul Cohort 4, 2023 European Journal of Cancer NCT02291289	RCT	metastatic/advanced - colorectal cancer (mCRC)	atezolizumab plus cobimetinib	fluoropyrimidine plus bevacizumab in 2- or 3-week treatment cycles depending on the fluoropyrimidine used	Patients 18 years of age or older with histologically confirmed, measurable, unresectable mCRC	65 / 34	some concern	inconclusive	inconclusive 44 % increase in progression or deaths (PFS) (PE) Cobimetinib plus atezolizumab had an unfavourable benefit:risk ratio in HER2‒/MSS/BRAFwt mCRC.
mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)
versus regorafenib
	atezolizumab plus cometinib
	IMblaze-370 (AC ; all population), 2019 Lancet Oncol. 2019; 20:849-861 NCT02788279	RCT	mCRC - 2nd line (L2)	atezolizumab plus cometinib	regorafenib	patients with unresectable locally advanced or metastatic colorectal cancer with disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled.	183 / 90	some concern	inconclusive	inconclusive 0 % increase in deaths (OS) (PE)